Physician profile
Ronald Surowitz
NPI 1679656656
$5,896.32
in general payments reported to CMS, 2019-2025
46 companies · $30.59 in 2025
The $30.59 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $104 · 2021: $1,735 · 2022: $2,812 · 2023: $225 · 2025: $30.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $225 · Food and Beverage: $30.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $224.87 |
| Food and Beverage | $30.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,451.31 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $1,080.00 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $518.73 | 2019-2021 | |
| Novo Nordisk INC | $414.61 | 2019-2022 | |
| Modernatx, INC. | $224.87 | 2023 | |
| Nevro Corp. | $204.64 | 2020-2021 | |
| Optinose US, INC. | $153.36 | 2019 | |
| Amarin Pharma, INC. | $132.47 | 2019 | |
| Cardiovascular Systems INC. | $129.15 | 2021 | |
| Abbott Laboratories | $119.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.95 | 2022 | |
| Conmed Corporation | $67.35 | 2019 | |
| Glaxosmithkline, LLC. | $65.67 | 2019-2025 | |
| Pfizer INC. | $40.37 | 2019 | |
| Antares Pharma, INC. | $39.97 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.60 | 2022 | |
| Amgen INC. | $31.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.37 | 2019 | |
| Lilly USA, LLC | $13.68 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.29 | 2021 | |
| Kvk-Tech, INC. | $9.92 | 2019 |
23 companies reported research payments only; those appear in the research section below.
Research and ownership
$466.38 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$92,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Surowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.